AbelZeta Announces Publication of Abstract for ASCO 2024 Annual Meeting

Rhea-AI Summary

AbelZeta Pharma, a clinical-stage biopharmaceutical company, has published an abstract of its C-CAR031 study for the ASCO 2024 Annual Meeting. The study focuses on hepatocellular carcinoma (HCC) and involves 24 patients. AbelZeta plans to present safety and preliminary efficacy data at the meeting in Chicago from May 31 to June 4, 2024. The oral presentation is scheduled for June 3, 2024, at 9:45 AM-11:15 AM CDT. More details can be found on the ASCO official website.

Positive

• Publication of abstract for C-CAR031 study at ASCO 2024 Annual Meeting highlights AbelZeta's ongoing research efforts.
• Oral presentation at a prestigious conference could boost AbelZeta's visibility and credibility in the biopharmaceutical industry.
• Focused on hepatocellular carcinoma (HCC), a significant area of unmet medical need, which may attract investor interest.

Negative

• Study is in Phase I, indicating that it is still in the early stages of clinical development.
• Safety and efficacy data are preliminary and may not lead to favorable results in later trials.
• No mention of financial impact or potential revenue generation from the study in the press release.

ROCKVILLE, Md., May 24, 2024 /PRNewswire/ -- AbelZeta Pharma, Inc. ("AbelZeta" or the "Company"), a global clinical-stage biopharmaceutical company focused on the discovery and development of innovative and proprietary cell-based therapeutic products, today announced that data from its C-CAR031 study has been published in an abstract available on the 2024 American Society of Clinical Oncology's (ASCO) official website, in connection with the Company's oral presentation at the ASCO Annual Meeting taking place in Chicago May 31 to June 4, 2024. The presentation will share safety and preliminary efficacy data for C-CAR031 across 24 patients with hepatocellular carcinoma (HCC). Abstracts are available at meetings.ASCO.org.

Details of the oral presentation are as follows:

Abstract Title: "Phase I study of C-CAR031, a GPC3-specific TGFβRIIDN armored autologous CAR-T, in patients with advanced hepatocellular carcinoma (HCC)."
Abstract Number: 4019
Session Type and Title: Rapid Oral Abstract – Gastrointestinal Cancer – Gastroesophageal, Pancreatic, and Hepatobiliary
Session Date and Time: 6/3/2024; 9:45 AM-11:15 AM CDT

About C-CAR031

C-CAR031 is an autologous, armored GPC3-targeting chimeric antigen receptor T-Cell (CAR-T) therapy, being studied in the treatment of HCC. It is based on a novel GPC3-targeting CAR-T designed by AstraZeneca (LSE/STO/Nasdaq: AZN) using their transforming growth factor-beta receptor II dominant negative (TGFβRIIDN) armoring discovery platform and is manufactured by AbelZeta in China. C-CAR031 is being developed in China under a co-development agreement between AbelZeta and AstraZeneca.¹

About AbelZeta Pharma, Inc.

AbelZeta is a global clinical-stage biopharmaceutical company with centers of excellence in Rockville, Maryland and Shanghai, China. AbelZeta is focusing on developing innovative and proprietary cell-based therapeutic products and is committed to ushering in bespoke treatments that harness the body's own immune system to fight against hematological malignancies and solid tumors, as well as inflammatory and immunological diseases. AbelZeta advances research and development in its own GMP facilities at its centers of excellence for early-stage clinical studies, with a pipeline comprised of CAR-T and TIL therapies.

Forward-Looking Statements

Statements in this communication relating to plans, strategies, specific activities, and other statements that are not descriptions of historical facts are forward-looking statements. Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include any risks detailed from time to time in the Company's reports. Such statements are based on the management's current beliefs and expectations and are subject to significant risks and uncertainties outside of management and the Company's control. Given these uncertainties, you should not place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as otherwise required by law, the Company does not undertake any obligation, and expressly disclaims any obligation, to update, alter or otherwise revise any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future events or otherwise.

Company Contact:

Sarah Kelly
Director of Communications
AbelZeta Pharma, Inc.
+1 (240) 552 5870
sarah.kelly@abelzeta.com
www.abelzeta.com

References

1. AbelZeta. AbelZeta Pharma Announces Agreement with AstraZeneca to Co-Develop a novel Glypican 3 (GPC3) Armored CAR-T Therapy in China. December 2023. https://www.abelzeta.com/abelzeta-pharma-announces-agreement-with-astrazeneca-to-co-develop-a-novel-glypican-3-gpc3-armored-car-t-therapy-in-china/

View original content to download multimedia:https://www.prnewswire.com/news-releases/abelzeta-announces-publication-of-abstract-for-asco-2024-annual-meeting-302155035.html

SOURCE AbelZeta Pharma, Inc.

FAQ

What is AbelZeta's new study about?

AbelZeta's new study, C-CAR031, is focused on treating advanced hepatocellular carcinoma (HCC).

When will AbelZeta present its C-CAR031 study data?

AbelZeta will present its C-CAR031 study data on June 3, 2024, at the ASCO Annual Meeting.

What type of data will AbelZeta present at ASCO 2024?

AbelZeta will present safety and preliminary efficacy data for its C-CAR031 study.

Where can I find the abstract for AbelZeta's C-CAR031 study?

The abstract for AbelZeta's C-CAR031 study is available on the ASCO 2024 meeting website.

How many patients were involved in AbelZeta's C-CAR031 study?

The C-CAR031 study involved 24 patients with advanced hepatocellular carcinoma (HCC).

What is the significance of AbelZeta's presentation at ASCO?

Presenting at ASCO 2024 provides AbelZeta with an opportunity to showcase its research to a global audience, potentially increasing its visibility and credibility.